Page 63 - Read Online

Constantinides et al. Neuroimmunol Neuroinflammation 2020;7:120-31 I http://dx.doi.org/10.20517/2347-8659.2019.22 Page 131

52. Castillo-Carranza DL, Guerrero-Muñoz MJ, Sengupta U, Gerson JE, Kayed R. α-synuclein oligomers induce a unique toxic tau strain.
Biol Psychiatry 2018;84:499-508.
53. Borroni B, Gardoni F, Parnetti L, Magno L, Malinverno M, et al. Pattern of Tau forms in CSF is altered in progressive supranuclear palsy.
Neurobiol Aging 2009;30:34-40.
54. Borroni B, Malinverno M, Gardoni F, Alberici A, Parnetti L, et al. Tau forms in CSF as a reliable biomarker for progressive supranuclear
palsy. Neurology 2008;71:1796-803.
55. Kuiperij HB, Verbeek MM. Diagnosis of progressive supranuclear palsy: can measurement of tau forms help? Neurobiol Aging
2012;33:204.e17-8.
56. Luk C, Compta Y, Magdalinou N, Martí MJ, Hondhamuni G, et al. Development and assessment of sensitive immuno-PCR assays for the
quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. J Neurochem 2012;123:396-405.
57. Barthélemy NR, Gabelle A, Hirtz C, Fenaille F, Sergeant N, et al. Differential mass spectrometry profiles of tau protein in the
cerebrospinal fluid of patients with Alzheimer’s disease, progressive supranuclear palsy, and dementia with lewy bodies. J Alzheimers Dis
2016;51:1033-43.
58. Cicognola C, Brinkmalm G, Wahlgren J, Portelius E, Gobom J, et al. Novel tau fragments in cerebrospinal fluid: relation to tangle
pathology and cognitive decline in Alzheimer’s disease. Acta Neuropathol 2019;137:279-96.
59. Arai H, Morikawa Y, Higuchi M, Matsui T, Clark CM, et al. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-
related pathology. Biochem Biophys Res Commun 1997;236:262-4.
60. Shelley BP, Hodges JR, Kipps CM, Xuereb JH, Bak TH. Is the pathology of corticobasal syndrome predictable in life? Mov Disord
2009;24:1593-9.
61. Ling H, O’Sullivan SS, Holton JL, Revesz T, Massey LA, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation.
Brain 2010;133:2045-57.
62. Lee SE, Rabinovici GD, Mayo MC, Wilson SM, Seeley WW, et al. Clinicopathological correlations in corticobasal degeneration. Ann
Neurol 2011;70:327-40.
63. Paik SR, Lee JH, Kim DH, Chang CS, Kim YS. Self-oligomerization of NACP, the precursor protein of the non-amyloid beta/A4 protein (A
beta) component of Alzheimer’s disease amyloid, observed in the presence of a C-terminal A beta fragment (residues 25-35). FEBS Lett
1998;421:73-6.
64. del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, et al. Recommendations to standardize preanalytical confounding
factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update. Biomark Med 2012;6:419-30.